StockData
Iambic Therapeutics, Inc. logo

Iambic Therapeutics, Inc. (IAM) shareholders

IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.10−1.74 (-11.73%)

Close on Nov 13, 2026Market cap –P/E –Yield –

Ownership

Who owns Iambic Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
1 buys · 0 sales
Net bought $11.50M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Qatar Investment Authority2,804,3605.80%13G (passive)Oct 15, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Frederick R. ManbyChief Technology Officer, Director1,862,665Oct 16, 2026
Thomas F. MillerChief Executive Officer, Director1,410,756Oct 16, 2026
Michael SecoraCFO & Chief Corp Dev Ofcr279,902Oct 19, 2026
Peter A. OlsonChief Scientific Officer30,909Oct 16, 2026
Neil JosephsonChief Medical Officer71,459Oct 16, 2026
William H. RastetterDirector200,920Oct 19, 2026
R. Jacob VogelsteinDirector742,546Oct 19, 2026
Evan Lockwood RachlinDirector57,754Oct 19, 2026
Kurt Von EmsterDirector–Oct 16, 2026
Shalini SharpDirector–Oct 16, 2026
Mary TagliaferriDirector–Oct 16, 2026
Samit HirawatDirector–Oct 14, 2026
Catalio Access Fund VIII, LLC10% owner–Oct 19, 2026
Catalio BH SPV, LLC10% owner–Oct 19, 2026
Catalio Nexus Fund III, LP10% owner–Oct 19, 2026
Catalio Capital Management, LP10% owner742,546Oct 19, 2026
George C. Petrocheilos10% owner–Oct 19, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
R. Jacob Vogelstein
Director
Oct 16, 2026Conversion+742,546––742,546
R. Jacob Vogelstein
Director
Oct 16, 2026Conversion+1,458,290––1,458,290
R. Jacob Vogelstein
Director
Oct 16, 2026Conversion+1,995,749––1,995,749
Evan Lockwood Rachlin
Director
Oct 16, 2026Conversion+57,754––57,754
Evan Lockwood Rachlin
Director
Oct 16, 2026Buy+718,750$16.00$11.50M2,588,248
Evan Lockwood Rachlin
Director
Oct 16, 2026Conversion+410,762––1,869,498
Evan Lockwood Rachlin
Director
Oct 16, 2026Conversion+1,458,736––1,458,736
Catalio Capital Management, LP
10% owner
Oct 16, 2026Conversion+742,546––742,546
Catalio Capital Management, LP
10% owner
Oct 16, 2026Conversion+1,458,290––1,458,290
Catalio Capital Management, LP
10% owner
Oct 16, 2026Conversion+1,995,749––1,995,749
Michael Secora
CFO & Chief Corp Dev Ofcr
Oct 16, 2026Conversion+61,342––279,902
William H. Rastetter
Director
Oct 16, 2026Conversion+8,341––200,920
William H. Rastetter
Director
Oct 16, 2026Conversion+192,579––192,579
Frederick R. Manby
Chief Technology Officer, Director
Oct 14, 2026Award+132,200––1,862,665
Peter A. Olson
Chief Scientific Officer
Oct 14, 2026Award+19,500––30,909
Thomas F. Miller
Chief Executive Officer, Director
Oct 14, 2026Award+132,200––1,410,756
Neil Josephson
Chief Medical Officer
Oct 14, 2026Award+31,000––71,459
Michael Secora
CFO & Chief Corp Dev Ofcr
Oct 14, 2026Award+28,400––218,560

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
1.2
At 1M shares a day
Change since last report
–
Short volume, 20 days
53.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Iambic Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?